TerminatedNCT00861497
Bifeprunox Extension to Extension Study in Patients With Schizophrenia
Researchers are studying Bifeprunox, tracking side effects to assess safety in people with schizophrenia.
Medication studyAges 18+Italy
Understand this study
What is this study about?
Researchers are studying Bifeprunox, tracking side effects to assess safety in people with schizophrenia.
Who could participate?
This study is for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria apply.
- Listed locations
- BresciaSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateJanuary 2006
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 11
- Sponsor
- H. Lundbeck A/S
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Italy
- Age range
- Over 18 Years
- Official registry ID
- NCT00861497
- Official title
Show the full official title
An Open-label Safety Study of Bifeprunox Investigating Flexible Doses of 20, 30, or 40mg/Day in Patients With Schizophrenia Who Have Completed Studies 10206 or 10265
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Brescia
Interested in joining this study?
Questions about this study
What is this study about?
Researchers are studying Bifeprunox, tracking side effects to assess safety in people with schizophrenia.
Who is behind this study?
The study sponsor is H. Lundbeck A/S.
Does this study involve medication?
Yes. The study involves medication, including Bifeprunox.
Who can participate?
This study is for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as terminated.
Want to explore more studies?
Explore studiesRelated studies
A Phase III, multi-center, randomized, 24 week, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of RO4917838 in stable patients with persistent, predominant n...
A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study